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 Abstract 
The prevalence of colorectal cancer (CRC) has been increasing in recent years 
worldwide. In the United States, it is ranked the second leading cause of cancer death. Risks of 
CRC increase with age and are associated with several lifestyle factors such as diet, drinking and 
smoking habits, and levels of physical activity. There is an abundance of scientific literature 
demonstrating the protective roles of several dietary components including fibers and 
polyphenolic compounds. These compounds have been shown to be able to positively modulate 
gastrointestinal ecology by increasing the production of short-chain fatty acids (SCFA) and 
promoting the population of beneficial bacteria. Whole grain cereals such as wheat, corn, 
sorghum, and rice are rich sources of these components. However, they are more abundant in the 
cereal bran layer which is typically removed during polishing. Research have shown that 
feruloylated arabinoxylan oligosaccharides (FAXO) isolated from cereals such as wheat, corn, 
and sorghum exerted prebiotic-like properties by increasing SCFA production and selectively 
promote microbiota population. Polyphenolic compounds have also been demonstrated to be able 
to modulate gut microbiota ecology. However, rice bran FAXO and rice bran polyphenolics 
(RBPP) have not been studied for such properties. Therefore, two rice bran components 
including FAXO and RBPP are hypothesized to have positive impacts on human gut microbiota. 
In this study, prebiotic-like properties of FAXO and RBPP were assessed by determining the 
fermentation patterns of FAXO and RBPP to increase SCFA production and by evaluating the 
impacts of FAXO and RBPP on the composition of human gut microbiota.  
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Introduction 
Awareness about colon health has been on a rise. In 2014, National Cancer Institute 
reported that colorectal cancer (CRC) is the third prevalent non-skin cancer in the United States. 
Moreover, it has been rated as the second most fatal type of cancer. Individuals with digestive 
disorders such as inflammatory bowel disease, ulcerative colitis, and polyps are most prone to 
CRC. Lifestyle factors including diet, levels of physical activity, smoking, alcohol consumption, 
and body composition have been associated with CRC (Doll and Peto 1981).  
Dietary components such as dietary fiber, probiotics and prebiotics, and phenolic 
compounds have been shown to confer positive colonic health effects. This is achieved by 
modulating gut microbiota and enhancing production of short-chain fatty acids (SCFA) 
(Macfarlane and Macfarlane 2003). 
Prebiotics are defined as “selectively fermented ingredients that result in specific changes 
in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefits 
upon host health” (Gibson et al. 2010).  
Currently, Bifidobacterium and Lactobacillus population are considered beneficial 
bacteria and are often targets for dietary intervention (Manning and Gibson 2004). 
Fructooligosaccharides (FOS), inulin, galactooligosaccharides (GOS), and lactulose are 
compounds that are currently considered true prebiotics since they have been reported to 
stimulate Bifidobacterium and Lactobacillus population (Gibson et al. 2010). In addition, other 
dietary materials have also been proposed to be candidate prebiotics. Non-digestible 
oligosaccharides are the primary new candidates since they appear to confer certain degrees of 
fermentation selectivity (Gibson et al. 2010). Among these oligosaccharides, feruloylated 
arabinoxylan oligosaccharides (FAXO) isolated from cereal bran such as wheat, barley, and corn 
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have gained much attention as they have been shown to exert prebiotic-like properties. FAXO 
have been implicated for having prebiotic-like activities because of their ability to pass through 
the upper gastrointestinal tract undigested to the colon where they are hydrolyzed and 
subsequently fermented by gut microbiota to produce SCFA (Englyst and Cummings 1985, 
Courtin et al. 2009). 
Another dietary component that can also positively affect the intestinal ecology is 
polyphenolics and their derived products. The intake of flavanol-rich foods has been shown to 
modify the composition of the gut microbiota by selectively inhibiting pathogen growth and 
stimulate the growth of beneficial bacteria, thus influencing the microbiota composition (Tzonuis 
et al. 2008) 
As mentioned above, FAXO isolated from cereal bran such as wheat, corn, and barley 
have been assessed for their prebiotic properties. However, FAXO and RBPP isolated from rice 
bran have not been studied for their potential colon health promoting properties including 
prebiotic activities. In addition, the synergistic activities of non-digestible oligosaccharides, 
particularly FAXO, and RBPP in improving colonic health has not been well studied. Therefore, 
the hypotheses of this study were that fermentation of rice bran components by colonic 
microbiota increases production of SCFAs, particularly butyric acid and that beneficial gut 
microbiota differentially increases after incubation with FAXO and RBPP. The objectives of the 
present study were to determine (1) the SCFA production of FAXO and RBPP by human gut 
microbiota, (2) the ability of FAXO and RBPP to stimulate beneficial human gut microbiota, and 
(3) the relationship of human gut microbiota and SCFA production. 
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Chapter 1: Literature Review 
1. Rice Bran 
Rice (Oryza sativa) is one of the major cereal crops and a staple food for half of the 
world’s population (Childs 2014). In the United States, Arkansas is the leading rice-producing 
state, accounting for about 50% of total U.S. rice production (Childs 2014). Rice bran is a 
byproduct from rice milling process to produce polished rice. Rice bran is defined as the brown 
outer layer of rice kernel comprising pericarp, aleurone layer and embryo (Figure 1), which 
account for 10-15% of rough rice by weight (Champagne et al. 2004). Rice bran has been 
intensively studied for its nutritional values. It has been reported to contain significant amounts 
of nutrients such as protein, unsaturated fat, vitamins, minerals, dietary fiber, and polyphenolic 
compounds, which have been shown to exhibit beneficial effects in various in vitro, animal, and 
human studies (Kahlon et al. 1992, Kahlon and Chow 2000, Qureshi et al. 2002). Although it is 
used primarily as animal feed, rice bran and its components are now finding major applications 
as value-added products (Jariwalla 2001, Ryan 2011). 
 
Figure 1. Structure of the rice grain. (Adapted from Juliano and Aldama 1937) 
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2. Feruloylated Arabinoxylan Oligosaccharides (FAXO) 
Arabinoxylans (AX) are the most abundant structural polysaccharides present in most 
cereals. They were first identified in wheat by Hoffman and Gortner (1927). Since then, similar 
polysaccharides have been found in other cereals such as rice, barley, rye, and corn (Izydorczyk 
and Biliaderis 1995). They are composed of a xylan backbone linked together by β(1→4) 
glycosidic bonds that are variably substituted with α-L-arabinofuranoside at either C-(O)-2 or C-
(O)-3 (Saulnier et al. 2007). Ferulic acid is present as substituents as well and they are generally 
linked to the C-(O)-5 position of arabinose units (Figure 2) (Izydorczyk and Biliaderis 1995), 
hence the name feruloylated arabinoxylans. AX together with other polysaccharides build up the 
cell walls of grain tissues and thus become part of the skeletal framework that maintains tissue 
(Rattan et al. 1994). The frequency and nature of substituents differ greatly amongst AX from 
different origins (Rattan et al. 1994). Specifically, AX from rice, maize, and sorghum bran 
contain more arabinose substituents than those from wheat, rye or barley bran (Rao and 
Muralikrishna 2007). Molecular mass of AX is difficult to determine since extraction process 
could lead to degradation of the polymers. However, it is generally estimated that they contain 
from 1,500 to 15,000 residues (Izydorczyk and Biliaderis 1995, Ebringerova and Heinze 2000). 
A small portion of AX in cereals is water-extractable (Maes and Delcour 2002). The majority is 
water-unextractable due to non-covalent interactions such as hydrogen linkages and covalent 
bonds with neighboring AX molecules through dehydrodiferulic acid bridges and with other cell 
wall components such as proteins, cellulose, and lignin (Iiyama et al. 1994, Izydorczyk et al. 
1998, Maes and Delcour 2002).  
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Figure 2. Structure of feruloylated arabinoxylans (Adapted from Buanafin 2009) 
 
Feruloylated arabinoxylan oligosaccharides (FAXO) are hydrolyzed products of AX of 
high degree of polymerization. Degradation of AX into FAXO can be achieved by using 
degrading enzymes, acid hydrolysis, or hydrothermal treatment (Vázquez et al. 2000).  
  
3. Pigmented Rice and Rice Bran Polyphenolics (RBPP) 
Whole grain rice products, especially those from pigmented varieties, provide a rich 
reservoir of polyphenolic compounds that have been suggested to have many health benefits 
(Min et al. 2012, Chen et al. 2012, Deng et al. 2013). Many epidemiological studies have shown 
that consumption of whole grain cereal is highly correlated with reduced incidence of chronic 
diseases (Jacobs et al. 1998, Liu et al. 1999, Anderson et al. 2000), of which free radicals are 
thought to play a critical role in the onset and progression (Sayre et al. 2008, Sen and 
Chakraborty 2011). Their protective effects are due to the scavenging of free radicals by 
polyphenolics that are rich in whole grain cereals (Sen and Chakraborty 2011).  
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According to the USDA National Small Grains Collection, pigmented rice can be 
classified into seven color classes: white, light-brown, speckled brown, brown, red, variable 
purple, and purple. Among them, light-brown rice is most commercially grown and has been the 
primary focus of rice polyphenolics-related studies. Other pigmented varieties such as red and 
purple bran rice have recently gained attention because they contain high amounts of phenolic 
compounds, including anthocyanins and proanthocyanidins, which have been reported to have 
health-promoting potentials (Biswas et al. 2011, Sompong et al. 2011, Min et al. 2012, Chen et 
al. 2012).  
The majority of polyphenolics in rice grains is present in the bran fraction which is a by-
product of the milling process. Lipophilic, hydrophilic, and insoluble forms of these compounds 
have been identified (Hudson et al. 2000, Cicero and Gaddi 2001, Pérez-Jiménez and Saura-
Calixto 2005). Phenolic compounds such as tricin, ferulic acid, caffeic acid, and 
methoxycinnamic acid have been identified in rice bran (Hudson et al. 2000). In addition, total 
polyphenolic content in the bran fraction of red and purple rice variety, which is made up mostly 
of free phenolics including proanthocyanidins and anthocyanins, is significantly higher than that 
of light-colored bran rice (Min et al. 2012).  
Polyphenolics of high molecular weight such as proanthocyanidins are poorly absorbed 
in the small intestine and largely remain intact when reaching the colon. Only a small percentage 
of dietary polyphenolics (5-10%), mainly monomeric and dimeric structures, may be directly 
absorbed in the small intestine, generally after deconjugation reactions. After being absorbed into 
the small intestine, these less complex polyphenolic compounds may be subjected to extensive 
Phase I (oxidation, reduction and hydrolysis) and particularly Phase II (conjugation) 
biotransformations in the enterocytes and then the hepatocytes, resulting in a series of water-
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soluble conjugate metabolites (methyl, glucuronide and sulfate derivatives) rapidly liberated to 
the systemic circulation for further distribution to organs and excretion in urine (Manach et al. 
2005). In the large intestine, remaining unabsorbed polyphenols are enzymatically hydrolyzed by 
colonic microbiota, subsequently resulting in polyphenolic compounds with lower degrees of 
polymerization (Aura et al. 2005). These polyphenolics are also further metabolized by 
microbiota through the cleavage of glycosidic linkages and the breakdown of the heterocyclic 
backbone (Aura et al. 2005). For example, the microbial catabolism of proanthocyanidins results 
in the production of lactones and aromatic and phenolic acids with different hydroxylation 
patterns and side-chain lengths, depending on the precursor structures (Manach et al. 2004, 
Saura-Calixto et al. 2007). All these microbial-derived phenolic metabolites may be absorbed in 
the intestine or excreted in feces. When absorbed, they reach the liver through the portal vein 
where they may be further subjected to extensive first-pass Phase II metabolism (including 
glucuronidation, methylation, sulfation or a combination of these) until they finally enter the 
systemic circulation and are distributed to the organs or eliminated in urine. 
Polyphenolic compounds are well known for their antioxidant properties, the ability to 
scavenger reactive oxygen species, which have been shown to be effective in preventing chronic 
diseases including cancer, hypertension, neurodegenerative diseases, and aging (Sen and 
Chakraborty 2011, Biswas et al. 2011). However, it has been suggested that health benefits of 
whole grain polyphenolics are more site-specific, being more effective in the colon (Adom and 
Liu 2002). This could be due to the fact that most polyphenolics in cereal bran are bound and 
may not be released by gut microbiota until they reach the colon (Adom and Liu 2002). This 
unique property may explain the reduced risk of colon cancer associated with increased 
consumption of whole grains and whole grain products (Thompson 1994, Jacobs et al. 1995). 
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Polyphenolics and their derived products can also positively affect the intestinal ecology. 
For example, the intake of flavanol-rich foods has been shown to modify the composition of the 
gut microbiota (Tzonuis et al. 2008). Polyphenolics and their metabolites selectively inhibit 
pathogen growth and stimulate the growth of beneficial bacteria, thus influencing the microbiota 
composition. For instance, resveratrol, a potent antioxidant found in wine, increased 
Bifidobacterium and Lactobacillus populations (Larrosa et al. 2009) and abolished the expression 
of virulence factors of Proteus mirabilis to invade human urothelial cells (Wang et al. 2006). In 
addition, phenolics and flavonoids may also reduce the adhesion ability of Lactobacillus 
rhamnosus to intestinal epithelial cells (Parkar et al. 2008). Tea catechins have also been shown 
to modify mucin content of the ileum in rat model which could modulate bacterial adhesion and 
colonization (Ito et al. 2006). Therefore, polyphenols appear to have potential to confer health 
benefits via modulation of the gut microbiota.  
 
4. Gut Microbiota and Human Health 
Although the human digestive tract is colonized by microorganisms, the distal gut 
(including cecum, large intestine or colon, and rectum) is the most densely populated part of the 
gut with 1012-1014 microorganisms including bacteria, archaea and yeast per gram feces 
(Whitman et al. 1998). Bacteria comprise about 40-55% of solid stool in people having typical 
Western diets (Stephen and Cummings 1980). Bacteroidetes and Firmicutes are the two 
dominant divisions accounting for almost 95% phylotypes. On the lower taxonomic levels, more 
than 50 genera and over 400 species have been identified in human gut (Eckburg et al. 2005). 
However, the composition and activity of the gut microbiota is extremely complex and unique 
for each individual as it is driven by many different factors (Nicholson and Wilson 2003). 
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Although the gut is essentially sterile at birth, it is rapidly populated with bacteria through 
environmental exposure (Palmer et al. 2007). Subsequently, the shaping of microbial landscape 
depends on a series of complex and dynamic interactions throughout life including diet, lifestyle, 
disease, and antibiotic use (Nicholson and Wilson 2003).  
The gut microbiota plays very important roles in health and disease in humans. It is 
involved in energy harvest and storage, as well as in a variety of metabolic functions such as 
fermenting and metabolizing undigested carbohydrates. More importantly, the gut microbiota 
interacts with the immune system, providing signals to promote the maturation of immune cells 
and the normal development of immune functions (Chow et al. 2010). The importance of the gut 
microbiota is unquestionable and it is sometimes referred to as the “forgotten organ” (O’Hara et 
al. 2006). Thus, it is important to maintain a healthy, or balanced, gut microbiota. Aberrations in 
the gut microbiota, or often referred to as dysbiosis, have been shown to correlates with many 
metabolic diseases such as colon cancer, inflammatory bowel disease, type 2 diabetes, and 
obesity (Ley et al. 2006, Peterson et al. 2008). However, the underlying roles and functionality of 
specific bacteria relative to disease still remain unclear (Gerritsen et al. 2011). 
 
4.1. Obesity 
The prevalence of obesity in the United States has increased by more than 75% over the 
past 25 years. Currently, nearly two-thirds of the U.S. population is overweight and 1 in 3 adults 
are clinically obese (Ogden et al. 2007). Obesity can lead to serious health consequences, 
including increased risk for type 2 diabetes, cardiovascular disease, pulmonary hypertension, and 
mortality (Hensrud and Klein 2006, Ogden et al. 2007). Although diet plays an important role in 
the development of obesity, interest has been focused on other factors that might contribute to 
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this disease. Particularly, the composition of gut microbiota has been implicated as a critical 
determinant in the development of obesity (DiBaise et al. 2012). 
The association between obesity and gut microbiota composition was first observed with 
mouse models by Ley et al. (2005). In their study, genetically obese mice showed 50% fewer 
Bacteroidetes accompanied by a proportional increase in Firmicutes compared to wild type 
counterparts (Ley et al. 2005). Consistent with the mouse model data, evidence also suggests that 
differences in the gut microbiota exist between obese and lean humans (Ley et al. 2006, 
Schwiertz et al. 2009). Changes in the gut microbiota upon weight loss in obese individuals also 
have been reported but results are not consistent. Schwiertz et al. (2009) showed that the 
proportion of Bacteroidetes was increased by weight loss. In contrast, Duncan et al. (2008) 
reported no relationship between percentage of Bacteroidetes in feces and amount of weight lost 
(kg) after a period of 8 weeks, comprising 4 weeks on each of two diets, either high-protein, low 
carbohydrate, ketogenic (LC) or high-protein, moderate-carbohydrate, non-ketogenic  (MC). 
However, there was a significant reduction in a group of butyrate producing Firmicutes in the 
obese group after diet intervention (Duncan et al. 2008). Thus, although diet changes 
undoubtedly have impacts on the gut microbiota, and in turn, on colonic health and function, the 
differences between the gut microbiota in lean and obese individuals remain incompletely 
understood and further investigation in the area is needed. 
 
4.2. Type 2 Diabetes 
Type 2 diabetes, a metabolic disease which primary cause is insulin resistance, has also 
been shown to be associated with changes in gut microbiota composition (Membrez et al. 2008) 
although it is far left behind as the focus of research compared to obesity. Larsen et al. (2008) 
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showed that the proportions of phylum Firmicutes and class Clostridia were significantly reduced 
in the diabetic group compared to the control group. Furthermore, they also found that the ratios 
of Bacteroidetes to Firmicutes were positively correlated with the severity of diabetes and 
plasma glucose concentration (Larsen et al. 2008). In addition, Bifidobacterium and 
Faecalibacterium prausnitzii abundance appeared to be lower in type 2 diabetic patients than in 
lean subjects (Furet et al. 2010, Wu et al. 2010). Interestingly, Bifidobacterium and 
Faecalibacterium prausnitzii are suggested to have anti-inflammatory effects by producing 
metabolites able to block NF-κB activation and the secretion of proinflammatory mediators 
(Furet et al. 2010, O’Mahony et al. 2010).  
Furthermore, other studies have demonstrated that the gut microbiota played a major role 
in the onset of insulin resistance and type 2 diabetes by triggering low-grade inflammation, 
which is also a common feature characterizing obesity and several metabolic disorders (Backhed 
et al. 2007, Cani et al. 2007, Shen et al. 2013). According to Cani et al. (2007), gut microbiota 
can control the host metabolism and contribute to the development of low-grade inflammation 
through several potential mechanisms. They proposed that disruption in the gut microbiota-host 
symbiotic relationship could cause increases in gut permeability by altering the expression, 
localization and distribution of tight junction proteins, overactivating the CB1 receptors, and 
decreasing intestinal alkaline phosphatase activity leading to a decrease in lipopolysaccharide 
detoxification. Gut barrier alterations are responsible for metabolic endotoxaemia leading to low-
grade inflammation and metabolic disorders (Everard and Cani 2013). 
Altogether, these data reveal an existing association between gut microbiota and the 
pathology of obesity and type 2 diabetes in humans. However, numerous questions still remain 
debatable or unanswered such as whether gut microbiota alterations are associated with the diet 
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or with the pathology of obesity and type 2 diabetes themselves and whether the gut microbiota 
changes observed in obesity and type 2 diabetes are a cause or a consequence of the pathology. 
Therefore, more detailed studies in humans are needed to further investigate the gut microbiota-
host relationship. 
  
5. Fermentation Patterns of Gut Microbiota and Colonic Health 
As discussed above, human gut microbiota is highly diverse with over 50 genera and over 
400 species of bacteria that have been identified (Eckburg et al. 2005). The dominant organisms 
in terms of numbers are anaerobes including bacteroides, bifidobacteria, eubacteria, streptococci, 
and lactobacilli (Topping and Clifton 2001). Undigested organic food components such as 
carbohydrates and peptides are often metabolized by the gut microbiota through fermentation to 
produce energy for microbial growth and maintenance and other metabolic end products. 
Fermentation is a complex process and involves a variety of reactions and metabolic processes in 
the anaerobic microbial breakdown of organic matter. Along with heat, major products of 
fermentation include gas such as H2, CH4, and CO2, and short-chain fatty acids (SCFA) (acetic, 
propionic, butyric acid - Figure 4) (Topping and Clifton 2001). Amino acid breakdown products 
including branched-chain fatty acids and ammonia are also found but in much smaller amounts 
(Roberfroid 2005).  
 
 
 
 
 
Figure 3. Acetic acid, propionic acid, and butyric acid structure 
Acetic acid Propionic acid Butyric acid 
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SCFA, fermentation end-products of carbohydrates by the gut microbiota, are strongly 
associated with colonic health in humans (Roediger 1980, Jenkins 1999, Smith et al. 2013). They 
are organic fatty acids with 1 to 6 carbon atoms and are the principal end products which arise 
from bacterial fermentation of undigested food components such as polysaccharides, 
oligosaccharides, peptide, amino acids, and glycoprotein precursors in the colon (Miller and 
Wolin 1979, Cummings and Macfarlane 1991). Linear SCFA, with acetic acid, propionic acid, 
and butyric acid (Figure 3) being the major products, in the fermentation process of undigested 
carbohydrates, have been the focus of interest in regards of colonic health (Macfarlane and 
Macfarlane 2003). SCFA modulate colonic functions in several different ways. Increases in 
SCFA result in the decreases of pH of the colonic luminal environment, which supports the 
growth of beneficial bacteria species while limits the growth of detrimental bacteria species 
(Jenkins et al. 1987). Decreases in pH also facilitate the absorption of certain vitamins and 
minerals in distal gut (Tuohy et al. 2005). More importantly, butyrate, the preferred energy 
source of colonocytes (Della Ragione et al. 2001), has been intensively investigated for its 
potentially protective activity against colon carcinogenesis, intestinal inflammation, and 
oxidative stress and for its contribution in improving the intestinal barrier. Although many in 
vitro and animal studies strongly suggest the protective role of butyrate against colon diseases, 
direct evidence in humans is still lacking (Bornet et al. 2002, Hijova and Chmelarova 2007). 
Butyrate is also involved in phosphorylation and acylation of histone proteins at molecular level 
which is thought to be crucial for the ability of butyrate to modulate the expression of numerous 
genes involved in colonic health (Archer and Hodin 1999).  
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Butyrate is not only produced directly from fermentable substrates but also produced 
from acetate by gut microbiota. Diez-Gonzalez et al. (1999) reported that butyrate was formed 
from two acetyl-CoA molecules that yielded acetoacetyl-CoA and then was converted into 
butyryl-CoA. Subsequently, butyryl-CoA was converted into butyrate via either butyrate kinase 
or butyryl-CoA:acetate-CoA transferase. According to Duncan et al. (2002), butyrate could be 
converted from acetate by butyrogenic bacteria including Coprococcus sp., Roseburia sp., and 
Faecalibacterium prausnitzii. Among those, six Roseburia and F. prausnitzii strains were shown 
to exhibit butyryl-CoA:acetate-CoA transferase but not butyrate kinase activity (Duncan et al. 
2002). They also showed acetate net utilization, especially F. prausnitzii, for which acetate is a 
growth requirement (Smith 1985). These findings suggest the complexity of the colonic 
ecosystem as metabolites can be interconverted into one another.  
Health effects of SCFA on gut health, especially butyrate, have been demonstrated in in 
vitro and in animal models. However, evidence in human is still lacking. Thus, further studies 
are needed to determine the activities of SCFA and to unravel the effects of diet on gut health in 
human.  
 
5.1. FAXO as Substrates for Gut Microbes 
Although many carbohydrates could be fermented by gut microbiota to produce SCFA, 
only a few are widely recognized as prebiotics. Originally, prebiotics were defined as “non-
digestible food ingredients that beneficially affect the host by selectively stimulating the growth 
and (or) activity of one or a limited number of bacterial species already resident in the colon, 
and, thus, improve host health” (Gibson and Roberfroid 1995). However, in 2008, the definition 
of “dietary prebiotics” was updated as “selectively fermented ingredients that result in specific 
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changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring 
benefit(s) upon host health” (Gibson et al. 2010) to account for modulation of other mixed 
microbial ecosystems by a prebiotic approach. To be considered a prebiotic, a food must meet all 
three criteria: (1) resistance to gastric acidity, to hydrolysis by mammalian enzymes, and to 
gastrointestinal absorption; (2) fermentation by intestinal microbiota; and (3) selective 
stimulation of growth and/or activity of beneficial intestinal bacteria (Gibson et al. 2004). 
Following this description, only a few carbohydrate compounds were considered prebiotics 
including inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) (Roberfroid 
et al. 2007). In recent years, many compounds, mostly oligosaccharides and polysaccharides, 
have been proposed to have prebiotic properties. However, at present, the evidence is not as 
convincing as for fructans and galactans.  
There is a growing body of evidence allowing FAXO to be considered to have prebiotic 
properties. FAXO from wheat source has been shown not only to be resistant to hydrolysis under 
gastric conditions (37oC, pH = 2) (Courtin et al. 2009), but also to escape digestion and 
absorption in small intestine due to the lack of enzymes to degrade these compounds (Englyst 
and Cummings 1985). A study by Glitso et al. (1999) found that rye AX were recovered as much 
as 100% in ileum in pigs. Thus, these findings suggest that FAXO remain largely intact and 
unabsorbed when reached the colon, where they are fermented by the gut microbiota. Many 
studies have confirmed the fermentability of AX and FAXO isolated from brewery's spent grain 
and wheat, including in vitro and in vivo in both animals and humans (Kabel et al. 2002, Grasten 
et al. 2003, Van Craeyveld et al. 2008). Increases in SCFA production upon fermentation of 
these compounds also have been corroborated (Grasten et al. 2003, Van Craeyveld et al. 2008). 
In addition, AX and FAXO appear to be relatively selective substrates. Several in vitro studies 
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have demonstrated that they can be utilized by some Bifidobacterium species and, to a lesser 
extent, some Bacteroides species and Lactobacillus species, but not by E.coli and Clostridium 
species (Yamada et al. 1993, Van Laere et al. 2000, Moura et al. 2007).   
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Chapter 2: Publication Manuscript 
 
Abstract 
Rice bran is a rich source of bioactive components that have potentials to promote 
gastrointestinal health but are typically removed with the bran during polishing. Feruloylated 
arabinoxylan oligosaccharides (FAXO) isolated from rice bran fiber and rice bran polyphenolics 
(RBPP) isolated from red rice bran are hypothesized to have positive impacts on human gut 
microbiota. The objectives of this study are to determine the prebiotic-like properties of FAXO 
and RBPP by determining the fermentation patterns of FAXO and RBPP and production of 
short-chain fatty acid (SCFA) and by evaluating their impacts on the composition of human fecal 
microbiota. Fresh fecal samples collected from healthy adults (n = 10, 5M, 5F) with no signs or 
symptoms of bowel diseases or conditions were diluted with anaerobic medium. Each sample 
received 5 treatments separately: CTRL (control, no substrates), FOS (fructooligosaccharides), 
FAXO, RBPP, and MIX (FAXO with RBPP). Samples were prepared inside an anaerobic 
chamber and then incubated at 37°C. An aliquot of 1.5 mL was withdrawn from each treatment 
tube at 0, 4, 8, 12, and 24 hours and stored immediately at -80°C. SCFA concentrations were 
measured quantitatively using gas chromatography. Microbial populations were determined by 
16S rRNA gene sequences via Illumina MiSeq platform and analyzed with QIIME (Quantitative 
Insights Into Microbial Ecology). Results showed that SCFA production was significantly 
increased with FAXO and was comparable to fermentation with the well-established prebiotic 
FOS. The synergistic effects of FAXO and RBPP in terms of SCFA production were not 
observed since RBPP alone and in combination with FAXO did not increase SCFA productions. 
Changes in microbiota population profiles were found, especially in Bacteroides, Prevotella, and 
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Dorea population, indicating that FAXO might be differently fermented, modulating microbiota 
profiles. Synergistic effects of FAXO and RBPP were also observed as they increased 
Coprococcus and Roseburia abundance. Results from this study suggested that FAXO and RBPP 
isolated from rice bran can potentially promote colon health. 
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1. Introduction 
Colorectal cancer (CRC) is the third common non-skin cancer and ranks second most 
common in mortality in the United States (National Cancer Institute, 2014). CRC is more 
prevalent in individuals with digestive disorders or gastrointestinal diseases such as 
inflammatory bowel disease, ulcerative colitis, and polyps. It has also been found to be 
associated with many lifestyle factors including diet, levels of physical activity, smoking, alcohol 
consumption, and body composition (Doll and Peto 1981). In recent years, there has been a 
growing interest in functional foods, such as prebiotics and probiotics, dietary fibers, and other 
dietary components that target the colon and improve colonic and systemic health by modulating 
gut microbiota and enhancing production of short-chain fatty acids (SCFA), which have been 
proved to confer positive colonic health benefits (Macfarlane and Macfarlane 2003).  
Prebiotics are defined as “selectively fermented ingredients that result in specific changes 
in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefits 
upon host health” (Gibson et al. 2010). Currently, only a few carbohydrates are considered true 
prebiotics, including fructooligosaccharides (FOS) and galactooligosaccharides (GOS). These 
compounds have been reported to stimulate Bifidobacterium and Lactobacillus population, 
which are considered beneficial bacteria and are often targets for dietary intervention (Manning 
and Gibson 2004).  
Many other dietary materials have been proposed to be candidate prebiotics. However, 
non-digestible oligosaccharides are mainly new candidates since they appear to confer the degree 
of fermentation selectivity (Gibson et al. 2010). Among these oligosaccharides, feruloylated 
arabinoxylan oligosaccharides (FAXO) isolated from cereal bran such as wheat, barley, and corn 
have gained much attention as they have been shown to exert prebiotic-like properties. FAXO 
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have been implicated for having prebiotic-like activities because of their ability to pass through 
the upper gastrointestinal tract undigested to the colon where they are hydrolyzed and 
subsequently fermented by gut microbiota to produce short-chain fatty acids (SCFA), which play 
important roles in regards of colon health (Englyst and Cummings 1985; Courtin et al. 2009).  
Polyphenolics and their derived products can also positively affect the intestinal ecology. 
The intake of flavanol-rich foods has been shown to modify the composition of the gut 
microbiota by selectively inhibiting pathogen growth and stimulate the growth of beneficial 
bacteria, thus influencing the microbiota composition (Tzonuis et al. 2008) 
FAXO and polyphenolics are present in abundance in whole grain cereals and their 
products, including whole grain rice. However, these components, which are present mostly in 
the bran, are typically removed from rice during polishing. FAXO and RBPP isolated from rice 
bran have not been studied for their potential colon health promoting properties including 
prebiotic activities. In addition, the synergistic activities of non-digestible oligosaccharides, 
particularly FAXO, and RBPP in improving colonic health has not been well studied. Therefore, 
the objectives of the present study were to determine (1) the SCFA production of FAXO and 
RBPP by human gut microbiota, (2) the ability of FAXO and RBPP to stimulate beneficial 
human gut microbiota, and (3) the relationship of human gut microbiota and SCFA production. 
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2. Materials and Methods 
2.1. Substrates and Standards 
Feruloylated arabinoxylan oligosaccharides (FAXO) were obtained from Dr. Savary, 
Arkansas State University (Jonesboro, AR, USA). Rice bran polyphenolic (RBPP) fraction 
isolated from red rice bran was obtained from Dr. Chen, Agricultural Research Service, USDA 
(Stuttgart, AR, USA) (Chen et al. 2012). The polyphenolic profile of RBPP is shown in Figure 1.  
Fructooligosaccharides (FOS) were purchased from Megazyme International Ireland Ltd. (Bray 
Business Park, Wicklow, Ireland). All materials were tightly sealed and stored at -20oC until use. 
SCFA standards including acetic acid, propionic acid, and butyric acid were of analytical grade 
and were purchased from Sigma-Aldrich (St. Louis, MO, USA).   
 
2.2. Subjects, Dietary Records, and Fecal Sample Collection 
The study protocol was approved by University of Arkansas Institutional Review Board 
(IRB #13-09-080). All participants were recruited from University of Arkansas (Fayetteville, 
AR, USA) and surrounding area (Appendix A). Thirty-two volunteers (15 males and 17 
females), 21-45 years of age, participated in a screening session to sign a consent form and a 
screening form. Only participants who were generally healthy (BMI < 25) with no digestive 
diseases, non-smokers, not currently taking any medications, and had not taken antibiotics in the 
last 6 months were recruited. During screening sessions, height and weight of subjects were 
recorded for Body Mass Index (BMI) calculation. Medical history and bowel movement habits 
were also recorded to confirm eligibility of participants. In addition, Food Frequency 
Questionnaires (FFQ) were completed by recruited participants.  
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Ten eligible subjects (5 males and 5 females) were recruited for the study. Each 
participant received a stool collection kit (Commode Specimen Collection System; Fisher 
Scientific, Pittsburgh, PA, USA) one or two days before the day of experiment. Subjects were 
instructed to deliver a tightly sealed fecal sample within one hour of defecation. Fecal samples 
were immediately transferred to an anaerobic chamber upon delivery to perform the experiment.  
 
2.3. In vitro Fermentation 
In vitro fermentation of substrates with the fecal inocula was carried out following the 
method described by Yang et al. (2013). In short, 50 mg each of FAXO, RBPP, their 
combination (MIX - FAXO with RBPP), and FOS used as control were mixed in 10 mL of 
sterile fermentation medium consisting of (per liter) peptone (2 g; Fisher Scientific, Waltham, 
MA, USA), yeast extract (2 g; Alfa Aesar, Ward Hill, MA, USA), bile salts (0.5 g; Oxoid, 
Hampshire, UK), NaHCO3
 (2 g), NaCl (0.1 g), K2HPO4 (0.08 g), MgSO4.7H2O (0.01 g), 
CaCl2.6H2O (0.01 g), L-cysteine hydrochloride (0.5 g; Sigma-Aldrich, St. Louis, MO, USA), 
bovine hemin (50 mg; Sigma-Aldrich, St. Louis, MO, USA), Tween 80 (2 mL), vitamin K (10 
μL; Sigma-Aldrich, St. Louis, MO, USA), and 0.025% (wt/vol) resazurin solution (4 mL). Fecal 
slurry was prepared by vortexing 1 g of fecal sample with 10 mL of sterile phosphate-buffered 
saline until homogenized then filtering through four layers of cotton gauge. Test tubes containing 
fermentation medium and treatments were then inoculated with 0.2 mL of fecal slurry. All steps 
for fermentation were conducted in an anaerobic chamber (Coy Laboratory Products Inc., Grass 
Lake, MI, USA). Test tubes were then capped, tightly sealed, and vortexed for 5 seconds to mix. 
Subsequently, test tubes were transferred to the incubator set at 37oC. Immediately before 
incubation, 1.5 mL of the mixture was taken out from each test tube using a sterile syringe for 
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time point 0 into a 2-mL centrifuge tube containing 0.1 mL of 2 M KOH stop solution. 
Subsequent aliquots were obtained in the same manner at 6, 12, and 24 hours and stored at -80oC 
until analysis. 
 
2.4. Short-Chain Fatty Acid Analysis 
Fermentation samples were thawed at room temperature and mixed with a vortex mixer. 
An amount of 225 µL was withdrawn from each aliquot and was treated with 25 µL of a mixture 
containing 5% meta-phosphoric acid and 5% copper sulfate with 50 mM 4-methyl-valeric acid 
added as an internal standard. After 10 min of reaction time, the mixture was centrifuged at 
12,000 x g for 2 min. A supernatant of 200 µL was transferred into a labeled tube and stored at -
20oC until analysis.  
SCFA standards were prepared using 1:2 serial dilution with the stock solution containing 
10% v/v of each SCFA (acetic acid, propionic acid, and butyric acid) in Milli-Q water. SCFA 
standards were also treated with the same mixture containing meta-phosphoric acid, copper 
sulfate, and 4-methyl-valeric acid as with fermentation samples.  
SCFA contents were analyzed using a gas chromatograph (GC) equipped with a flame 
ionization detector (FID) (Shimadzu Corp., Kyoto, Japan) and a fused silica capillary column 
(ID-BP21; SGE, L: 30 m, I.D: 0.25 mm, film: 25 µm, Ringwood, Victoria, Australia). 
Temperature ramp was as following: 4oC/min from 100oC (2 min) to 120oC (1 min), then 
3oC/min until 150oC. One µL of treated sample (thawed and homogenized) was injected in split 
mode (30:1). Nitrogen was used as a carrier gas. Data were recorded and processed using the 
integrated Shimadzu database. Concentrations of acetic acid, propionic acid, and butyric acid 
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were determined using a standard curve of each SCFA with concentration ranging from 0 to 30 
mM.  
 
2.5. DNA Extraction and Sequence Analysis 
Bacterial proliferation capability of each treatment was assessed by DNA sequence 
analysis of time 0 and 30 hours. Bacterial DNA was extracted from sample aliquots using 
QIAamp Fast DNA Stool Mini Kit (Qiagen, Gaithersburg, MD, USA). DNA concentrations were 
measured using NanoDrop 1000 (Thermo Fisher Scientific, Waltham, WA, USA). All samples 
were diluted with DNase- and RNase-free water to achieve concentrations of 10 ng/µL. DNA 
samples were then mixed with AccuPrime Pfx SuperMix (Thermo Fisher Scientific, Waltham, 
WA, USA) and primers and were amplified via polymerase chain reaction (PCR) using 
Eppendorf Mastercycler pro S (Eppendorf, Hamburg, Germany). Amplification of DNA samples 
were confirmed by agarose gel electrophoresis. Amplified DNA samples were normalized using 
SequalPrep Normalization Plate Kit (Thermo Fisher Scientific, Waltham, WA, USA) before 
pooling to make DNA sample library. Sequencing based on 16S-rRNA V4 region was performed 
using an Illumina MiSeq platform with the method developed by Kozich et al. (2013). Raw 
sequencing data acquired from Illumina BaseSpace were processed with a bioinformatics tool 
QIIME pipeline (Caporaso et al. 2010).  
 
2.6. Statistical Analyses 
All statistical analyses were carried out by JMP software (version 12; SAS Institute, 
Cary, NC, USA), using one-way ANOVA for comparing three or more data sets or paired t-test 
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for comparing two data sets. Data are presented as Mean ± SEM (Standard Error of Mean) unless 
specified as standard deviation (SD). Statistically significance was accepted at P < 0.05. 
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3. Results 
3.1. Subject Characteristics 
In the present study, 10 subjects (5 males, 5 females) were recruited. Participant 
information including age, height, weight, and body mass index (BMI) is shown in Table 2. BMI 
of all subjects were within normal range (19.6 – 24.6).  
 
3.2. Short-Chain Fatty Acid Analysis 
SCFA concentrations were quantified based on peak areas using a standard curve for 
each SCFA (Figure 1). Total SCFA concentrations were measured at different time points from 0 
hr to 24 hr (Table 3). FAXO appeared to be a preferred substrate by the microbiota as evidenced 
by the increase in total SCFA. Compared to FOS, a widely-recognized prebiotic, total SCFA 
production of FAXO was very comparable at later time points of 12 hr and 24 hr as no 
significant differences were found. However, at time point 4 hr and 8 hr, SCFA production of 
FOS was significantly higher compared to FAXO (P < 0.05), indicating different fermentation 
patterns of FOS and FAXO. Specifically, FAXO appeared to have slower and steadier 
fermentation rates throughout the incubation period compared to FOS, which were rapidly 
fermented in the beginning (time point 4 and 8 hr) but then slowed down over time.  
RBPP were not fermented by the microbiota as no significant SCFA were produced. 
Furthermore, there was no significant difference in total SCFA production between FAXO and 
MIX (FAXO with RBPP) at any time points, indicating that RBPP also did not affect the SCFA 
production from FAXO.  
Individual SCFA production (acetate, propionate, and butyrate) was also determined 
(Figure 2). Acetate (Figure 2A) showed to be the predominant SCFA produced as its 
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concentration at time point 24 hr was 3-4 times higher compared to propionate and butyrate 
(Figure 2B and C), which were produced at similar levels. Acetate production of all treatments 
also exhibited similar trends as observed in in total SCFA production. In particular, acetate 
production of FOS were significantly higher than that of FAXO at time point 4 hr and 8 hr but 
not at time point 12 hr and 24 hr.  However, for propionate and butyrate production, no significant 
differences were found at time point 4 hr and 8 hr in when comparing FOS and FAXO. No 
synergistic effects between FAXO and RBPP were observed as there was no significant 
difference between FAXO and MIX at any time point for all three individual SCFA.  
 
3.3. Microbiota Analysis 
The 16S rRNA sequencing data were analyzed to investigate the changes in microbiota 
composition after 24-hour incubation with FAXO, RBPP, and MIX compared with CTRL 
(control, no substrate) and FOS. At phylum level, four major phyla were identified in all samples 
including Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria (Figure 3). After 24 
hours of incubation, different substrates appeared to be able to modulate the microbiota 
composition significantly. FAXO appeared to increase Bacteroidetes and decrease Firmicutes 
abundance significantly compared to CTRL (P < 0.05). Proteobacteria population was also 
suppressed significantly in FAXO compared to CTRL (P < 0.05). On the other hand, FOS, did 
not significantly affect the abundance of Bacteroidetes and Firmicutes compared to CTRL. FOS 
also showed a significant increase in Actinobacteria population and a significant decrease in 
Proteobacteria compared to CTRL (P < 0.05). RBPP alone and in combination with FAXO 
(MIX) only affected the Proteobacteria population as evidenced by a significant decrease in the 
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abundance of this phylum compared to CTRL (P < 0.05). However, RBPP seemed to decrease 
Proteobacteria to a lesser extent compared to FAXO. 
Relative abundance of representative genera was also investigated. Results showed that 
FOS increased Bifidobacterium abundance dramatically which indicated FOS were utilized by 
Bifidobacterium species (P < 0.05) (Figure 4A). An increase in Lactobacillus was observed; 
however, it was not significant compared to CTRL (Figure 4B). No significant changes were 
observed in Bifidobacterium and Lactobacillus with FAXO treatment. Similarly, RBPP and MIX 
did not appear to significantly affect the abundance of Bifidobacterium and Lactobacillus. 
Overall, FAXO, RBPP, and MIX did not seem to exert any effects on Bifidobacterium and 
Lactobacillus, two genera that are often targets for prebiotic action as they are commonly 
associated with many health benefits.  
However, considering other genera, significant differences were observed. Specifically, 
Bacteroides was increased significantly in FAXO and RBPP compared to both CTRL and FOS 
(P < 0.05) (Figure 4C). MIX treatment, however, did not affect Bacteroides abundance. FAXO 
also appeared to increase Prevotella abundance significantly compared to CTRL (P < 0.05) 
(Figure 4D). Population of Dorea was also affected by FOS, FAXO, and RBPP with significant 
decreases compared to CTRL (P < 0.05) (Figure 4E). In MIX, no significant difference in Dorea 
were found compared to CTRL. Akkermansia, a mucus-degrading genus which has gained 
significant attention in recent years because of its correlation to gut health, was also detected. 
However, no significant differences in Akkermansia population were found between treatments. 
The average abundance of Akkermansia ranged from 0.20% to 0.41% for all treatments. 
Faecalibacterium, a butyrate-producing genus, was increased significantly in abundance with 
RBPP and MIX compared to CTRL and FOS (P < 0.05) (Figure 4F). FAXO also seemed to 
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increase Faecalibacterium but no significant difference was observed. Taken together, these 
results suggested that although FAXO and RBPP did not alter Bifidobacterium and 
Lactobacillus, they appeared to be able to modulate other gut bacteria populations that could also 
play important roles in host health.  
 
3.4. Relationship of Human Gut Microbiota and SCFA Production  
The production of butyrate has been getting much attention because of its anti-
inflammatory and anti-neoplastic effects on colonocytes (Segain et al. 2000, Rosignoli et al. 
2001). Butyrate is not only produced directly from carbohydrate sources by butyrate-producing 
bacteria but can also be produced from acetate. As reported by Duncan et al. (2002), butyrate 
could be converted from acetate by butyrogenic bacteria including Coprococcus sp., Roseburia 
sp., and Faecalibacterium prausnitzii. The abundance of these bacteria groups was also assessed 
to evaluate the relationship of gut microbiota and SCFA production.  
As shown in Figure 5, synergistic stimulative effects of FAXO and RBPP were observed 
in Coprococcus and Roseburia as evidenced by a significant increase in MIX compared to CTRL 
in these two genera (P < 0.05) while both FAXO and RBPP did not differ from CTRL (Figure 
5A and B). F. prausnitzii, the most abundance species in Faecalibacterium genus, also exhibited 
similar trends as in its genus shown above. Comparing to CTRL, both RBPP and MIX appeared 
to increase the abundance of this particular species significantly (P < 0.05) (Figure 5C).  
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4. Discussion 
In recent years, FAXO have gained particular interest because of their prebiotic-like 
activities. Prebiotics, by definition, are selectively fermented ingredients that result in “specific 
changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring 
benefit(s) upon host health” (Gibson et al. 2010). Fermentation of prebiotics by gut microbiota 
results in production of SCFA and a shift in the composition colonic microbiota that is associated 
with improved over health.  
In the present study, FAXO were shown to be fermented by gut microbiota to produce 
SCFA. The fermentation patterns of FAXO were characterized by slower rates at time point 4 hr 
and 8 hr and faster rates at later time points compared to FOS. Rumpagaporn et al. (2015) also 
reported similar findings in fermentation patterns of cereal arabinoxylans isolated from wheat, 
corn, sorghum, and rice compared FOS (a positive control). As described in their study, fecal 
samples were collected from 3 healthy subjects and pooled. An amount of 50 mg of each 
substrate and 1 mL of pooled fecal slurry were used for the experiment. Arabinoxylans from 
different bran sources including corn and sorghum and hydrolyzed arabinoxylan products 
including corn, wheat, and rice were used in their study. In their study, total SCFA production in 
hydrolyzed rice bran arabinoxylan treatment were shown to have significant higher levels 
compared to FOS at time point 24 hr. In the present study, although total SCFA of FAXO was 
higher than that of FOS, no significant differences were found at time point 24 hr when 
comparing FAXO and FOS.  
Acetate was the major SCFA produced during fermentation of FAXO. Similar findings 
were also reported in wheat arabinoxylans (Hughes et al. 2007), arabinoxylan oligosaccharides 
from brewery spent grain (Kabel et al. 2002), and hydrolyzed rice arabinoxylans (Rumpagaporn 
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et al. 2015). Acetate production of FAXO and FOS also showed similar patterns as in total SCFA 
production. In colonic fermentation, acetate is considered the primary SCFA and is often used to 
monitor colonic events. In the colon, unlike propionate and butyrate, acetate is less metabolized 
and is readily absorbed. The presence of acetate also decreases colonic pH, which results in 
increased bio-availability of calcium and magnesium and inhibition of pathogenic bacteria 
(Teitelbaum and Walker 2002, Wong et al. 2006).  Also, acetate can also be converted to 
butyrate. Two mechanisms that have been reported for the production of butyrate in the colon are 
acetate utilization and lactate fermentation (Diez-Gonzalez et al. 1999).  
The propionate production of FAXO was also comparable to FOS in this study. Other 
studies have shown that arabinoxylans produced relatively high propionate (Rose et al. 2010, 
Rumpagaporn et al. 2015). Rumpagaporn et al. (2015) also reported that propionate 
concentration in rice arabinoxylans was significantly higher compared to FOS at time point 24 
hr. In this study, propionate production of FAXO at 24 hr tended to be higher compared to FOS; 
however, the differences were not significant. Upon produced by gut bacteria, propionate is 
absorbed into bloodstream and transported to liver (Wong et al. 2006). Propionic acid production 
has been shown to have beneficial health effects including lowering glucose-induced insulin 
secretion in isolated pancreatic islet cells of rats (Ximenes et al. 2007) and anti-proliferative 
effects on liver cells (Bindels et al. 2012).  
Among all SCFA, butyrate has been of greatest interest due to its protective effects of 
colonocytes against cancer. FOS has been known for the ability to increase butyrate production, 
hence the butyrogenic effects (Campbell et al. 1997, Djouzi and Andrieux 1997, Rycroft et al. 
2001). Fermentation of arabinoxylans was shown to generate lesser butyrate compared to FOS in 
a study by Rumpagaporn et al. (2015). However, in the present study, no significant differences 
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were found between FAXO and FOS. Butyrate has been shown to be the preferred energy source 
for colonocytes (Della Ragione et al. 2001) and inhibit the growth of colonic carcinoma cells. As 
discussed above, the production of butyrate also comes from the conversion of acetate. 
Therefore, the production of each individual SCFA depends on other SCFA and SCFA 
concentrations in anaerobic fermentation can be changed interdependently.  
Beside SCFA production upon fermentation, another criterion that a prebiotic must meet 
is the ability to selectively stimulate the growth and/or activity of intestinal bacteria associated 
with health and well-being. Bifidobacteria and lactobacilli were thought to be the targets of 
prebiotic effects since they have been the focus of research, especially bifidobacteria as they are 
more abundant in human gut microbiota than lactobacilli. However, in recent years, many studies 
have reported the potential health effects of different groups of bacteria other than bifidobacteria 
and lactobacilli.  
FAXO appeared to be a relatively selective substrate as demonstrated in several studies. 
Pure cultures of different Bifidobacterium, Bacteroides, and Lactobacillus species were shown to 
efficiently utilize FAXO (Yamada et al. 1993, Van Laere et al. 2000, Moura et al. 2007). 
Another study conducted by Vardakou et al. (2007) found that in vitro fermentation of 
arabioxylan oligosaccharides significantly raised Bifidobacterium sp. and reduced Bacteroides 
levels. In the present study, FAXO did not appeared to stimulate the growth of Bifidobacterium 
and Lactobacillus genus.  However, when assessing populations of other bacteria genera, FAXO 
seemed to confer certain positive health effects. Specifically, FAXO increased Bacteroides and 
Prevotella abundance while reduced Dorea abundance.  
Bacteroides is one of the most abundant genera in the gut microbiota. Aside from its 
correlation with increased propionate production, Bacteroides has also been shown to have 
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protective effects against the invasion of exogenous bacteria in the colon by producing antagonic 
substances including bacteriocins (Nakano et al. 2006). This bacterial characteristic might play 
an important role in establishing and maintaining the intestinal ecosystem. 
It was also interesting to see an increase in Prevotella sp. with FAXO. This genera is 
often associated with people with diets high in carbohydrates and fiber (Wu et al. 2011). 
However, the variation between subjects in FAXO is quite large and comparing to FOS, FAXO 
did not differ significantly (Figure 4D). A study conducted by De Filippo et al. (2010) revealed 
the differences in changes in gut microbiota of European and African children when solid food 
was introduced. European children’s diet was rich in fat and low in fiber while African children’s 
diet was rich in fiber and low in fat and animal proteins. During breast-milk feeding period, no 
significant differences in gut microbiota were found between two groups of children. However, 
when solid food was introduced, differences in bacteria populations were observed. There was a 
significant enrichment of Prevotella genus in gut microbiota of African children compared to 
that of European counterparts. The differences were explained by the ability to produce 
cellulases and xylanases of this genus. Therefore, an increase in Prevotella with FAXO was 
expected.  
Compared to other genera, Dorea was far less studied. However, correlation between 
Dorea population and disease has been demonstrated. Specifically, it has been shown that 
irritable bowel syndrome (IBS) was characterized by an increase in Dorea population and a 
decrease in Bifidobacterium and Faecalibacterium (Rajilić-Stojanović et al. 2011; Saulnier et al. 
2011). These findings suggest that there might be a link between gut microbiota and IBS which 
could potentially be used for therapeutic treatments.  
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Another genus that has gained attention in recent years is Akkermansia. Isolated in 2004, 
Akkermansia has been known for its mucus-degrading abilities (Derrien et al. 2004). As a result 
of mucus degradation, Akkermansia sp. also have the ability to produce SCFA (Derrien et al. 
2004). Since Akkermansia sp. are often localized within the mucus layer close to the epithelial 
cells, these SCFA are more readily available to the host. Furthermore, recent studies also found 
that the abundance of Akkermansia sp. might be correlated with gut health. Specifically, A. 
municiphila was shown to be significantly more abundant in healthy controls compared to 
patients with IBD (Png et al. 2010). Other studies found that amount of Akkermansia sp. was 
inversely proportional to the severity of appendicitis and obesity (Zhang et al. 2009; Swidsinki et 
al. 2011). These findings suggest that Akkermansia could be associated with anti-inflammatory 
and protective activities.  Akkermansia has also been shown to be promoted by the 
administration of prebiotics in animal models (Everard et al. 2011; van den Abbeele et al. 2011). 
However, in the present study, no significant differences in Akkermansia were found between 
treatments. This could be due to the limitations of in vitro models which might not be ideal for 
this particular genera.  
As discussed above, some bacteria are also capable of converting acetate to butyrate, 
namely Coprococcus, Roseburia, R. intestinalis, and Faecalibacterium prausnitzii (Duncan et al. 
2002). It is interesting that while both FAXO and RBPP did not appeared to modulate 
Coprococcus and Roseburia abundance, MIX treatment showed significant increases in both 
genera, especially in Roseburia where FOS also did not affect its population. These results 
suggested that there might be synergistic effects between FAXO and RBPP in modulating gut 
microbiota. Although these butyrogenic bacteria were increased in abundance, no significant 
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differences were observed in neither acetate production nor butyrate production between FAXO 
and MIX.  
The study was conducted using an in vitro anaerobic fermentation model which is 
commonly used for first assessment of impacts of various compounds on metabolic activities of 
gut microbiota. However, this method certainly has its limitations. First of all, since it is a closed 
system, metabolites produced are limited by amounts of substrates used. Second, the 
accumulation of end-products during fermentation period could alter the conditions of 
fermentation environment and affect the formation of certain metabolites. Third, in vitro methods 
do not fully replicate in vivo intestinal conditions which affects the in vivo relevance of the study. 
Moreover, due to limitations of substrates, only 10 subjects were recruited for the study. The 
small sample size could have also reduced the statistical power and undermined the effects of 
treatments.  
The present study investigated the fermentibility of FAXO and RBPP and the changes in 
gut microbiota during fermentation with these components. The results demonstrated that FAXO 
had different fermentation patterns compared to FOS. FAXO were also found to be able to 
modulate several bacteria populations which could contribute to overall host health.  
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5. Conclusion 
Production of SCFA from FAXO extracted from rice bran by gut microbiota was 
comparable with that from FOS, although the fermentation pattern of FAXO were generally 
steadier compared to that of FOS. Furthermore, FAXO also showed to have modulating effects 
on microbiota profiles. Synergistic effects of FAXO and RBPP in modulating certain butyrate-
producing bacteria were also observed. This study warrants further investigation to confirm the 
prebiotic-like properties of these rice bran components.  
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Table 1. Concentration of phenolics in red rice RBPP (Chen et al. 2012). 
Phenolic subgroup Concentration (mg/g extract) % total phenolics 
Benzoic acid 2.466 ± 0.045 5.1% 
Cinnamic acid 20.115 ± 0.022 41.9% 
Flavonoid 1.955 ± 0.115 4.1% 
Proanthocyanidin 23.489 ± 1.904 48.9% 
Total phenolics 48.025 ± 2.042 100% 
Values are expressed as mean ± SD.  
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Table 2. Subject Characteristics 
Measurements All (n=10) Male (n=5) Female (n=5) 
Age 25.8 ± 4.7 26.0 ± 5.1 25.6 ± 4.2 
Height (cm) 170.9 ± 5.8 173.6 ± 4.2 168.2 ± 5.9 
Weight (kg) 66.6 ± 7.3 69.8 ± 7.5 63.5 ± 5.8 
BMI (kg/m2) 22.8 ± 2.0 23.1 ± 1.8 22.5 ± 2.3 
Values are expressed as mean ± SD. 
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Table 3. Total production of SCFA during in vitro fermentation with human fecal samples. 
 Total SCFA (mM) 
Time point (hr) FOS FAXO RBPP MIX 
0 1.5 ± 0.3a 1.5 ± 0.3a 0.6 ± 0.2a 1.3 ± 0.3a 
4 4.0 ± 0.8a 2.4 ± 0.7b 0.3 ± 0.1c 2.9 ± 1ab 
8 10.2 ± 1.1a 6.7 ± 1.8b 0.0 ± 0.2c 4.9 ± 1.7b 
12 9.9 ± 1.1a 10.5 ± 2.7a 0.1 ± 0.2b 9.3 ± 3.1a 
24 9.3 ± 1.1a 14.0 ± 3.6a 0.8 ± 0.7b 11.7 ± 3.2a 
Values are expressed as mean ± SEM. Treatments with different superscripts within the same row 
are significantly different (P < 0.05). FOS: fructooligosaccharides, FAXO: feroloylated 
arabinoxylan oligosaccharides, RBPP: rice bran polyphenolics, MIX: mixture of FAXO and 
RBPP. 
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Figure 1. GC chromatogram of (A) SCFA standards and (B) FAXO fermentation sample at time 
point 24 hr. (1) Acetate; (2) Propionate; (3) Butyrate; (4) Valerate as internal standard.  
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Figure 2. Individual SCFA production during in vitro fermentation. (A) Acetate production; (B) 
Propionate production; (C) Butyrate production; FOS: fructooligosaccharides, FAXO: 
feroloylated arabinoxylan oligosaccharides, RBPP: rice bran polyphenolics, MIX: mixture of 
FAXO and RBPP. Different letters at the same incubation time denote significant difference (P 
<0.05) 
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Figure 3. Microbiota composition at phylum level after 24-hr incubation with different 
substrates. CTRL: no substrate, FOS: fructooligosaccharides, FAXO: feroloylated arabinoxylan 
oligosaccharides, RBPP: rice bran polyphenolics, MIX: mixture of FAXO and RBPP. Different 
letters in the same phylum denote significant difference (P <0.05). 
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Figure 4. Changes in abundance of different genera after 24-hr incubation with different 
substrates. CTRL: no substrate, FOS: fructooligosaccharides, FAXO: feroloylated arabinoxylan 
oligosaccharides, RBPP: rice bran polyphenolics, MIX: mixture of FAXO and RBPP. Different 
letters denote significant difference (P <0.05). 
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Figure 5. Changes in abundance of different butyrogenic bacteria after 24-hr incubation with 
different substrates. CTRL: no substrate, FOS: fructooligosaccharides, FAXO: feroloylated 
arabinoxylan oligosaccharides, RBPP: rice bran polyphenolics, MIX: mixture of FAXO and 
RBPP. Different letters denote significant difference (P < 0.05). 
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Chapter 3: Overall Conclusion 
The present study added to the growing body of evidence on prebiotic-like properties of 
rice bran components such as FAXO and RBPP. Compared to FOS, FAXO tended to be 
fermented at slower yet steadier rates. RBPP did not appeared to affect the production of SCFA 
from FAXO. In terms of microbiota composition, both FAXO and RBPP had significant impacts 
on bacteria abundance to a certain degree. At phylum level, FAXO appeared to significantly 
increase Bacteroidetes and increase Firmicutes abundace, which are two major phyla in gut 
microbiota. Although FAXO and RBPP did not seem to affect bifidobacteria and lactobacilli 
population, they appeared to be able to modulate bacteria populations of other genera. FAXO 
significantly increase Bacteroidetes and Prevotella population and decrease Dorea population. 
RBPP was found to significantly increase Faecalibacterium abundance. Synergistic effects of 
FAXO and RBPP were observed in butyrogenic bacteria population Coprococcus and Roseburia 
by significant increases compared to FAXO and RBPP. Results from this study reaffirm that 
FAXO had potentials to be prebiotics. However, further investigation is needed to clarify the 
prebiotic functions of these rice bran components.  
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